AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2187176 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg)
Number of subjects: 160
Study 2187176 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 160
Study 94008 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation treatment in one eye
Number of subjects: 42
Study 94008 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 42
Study 31144720 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic catheter lead coverage (group A)
Number of subjects: 19
Study 31144720 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic protection (group B)
Number of subjects: 19
Study 31488113 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-scenario debriefing
Number of subjects: 50
Study 31488113 — intervention group
Group type: COMPARATOR
Intervention: Stop-and-go debriefing
Number of subjects: 50
Study 28724365 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rituximab (500 mg on days 1 and 15)
Number of subjects: 40
Study 28724365 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (10-20 mg/day)
Number of subjects: 40
Study 26812182 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/B
Number of subjects: 9
Study 26812182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 24284971 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable packing (Nasopore)
Number of subjects: 56
Study 24284971 — intervention group
Group type: COMPARATOR
Intervention: Nondegradable packing (Merocel)
Number of subjects: 56
Study 24284971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both biodegradable and nondegradable packing
Number of subjects: 56
Study 23082538 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.2 mg/kg s.c.)
Number of subjects: 11
Study 23082538 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.5 mg/kg s.c.)
Number of subjects: 11
Study 23082538 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (0.1 mg/kg)
Number of subjects: 11
Study 23082538 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (1 mg/kg)
Number of subjects: 11
Study 23082538 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% s.c. equivalent volume)
Number of subjects: 11
Study 18332063 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation programme
Number of subjects: 525
Study 18332063 — intervention group
Group type: COMPARATOR
Intervention: Centre-based cardiac rehabilitation programme
Number of subjects: 525
Study 17463114 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐free computer‐assisted navigation system
Number of subjects: 100
Study 17463114 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 100
Study 15589858 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET)
Number of subjects: 40
Study 15589858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11726411 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with nitrous oxide and oxygen
Number of subjects: 0
Study 11726411 — intervention group
Group type: COMPARATOR
Intervention: Halothane with nitrous oxide and oxygen
Number of subjects: 0
Study 11726411 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 11726411 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 0
Study 9394721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 76
Study 9394721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 76
Study 8424424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 20
Study 8424424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3324596 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear incision plus curettage under antibiotic cover
Number of subjects: 50
Study 3324596 — intervention group
Group type: COMPARATOR
Intervention: Deroofing and drainage
Number of subjects: 50
Study 29410559 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexi‐Bar exercise program with vibration stimulation
Number of subjects: 30
Study 29410559 — intervention group
Group type: COMPARATOR
Intervention: General physical therapy
Number of subjects: 30
Study 27207495 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking combined with obstacle-crossing (30 min/day, 5 times/week, for 4 weeks)
Number of subjects: 29
Study 27207495 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 min of active/passive exercises and 30 min of gait training in the form of treadmill walking)
Number of subjects: 29
Study 25677846 — intervention group
Group type: EXPERIMENTAL
Intervention: worst side improvement
Number of subjects: 28
Study 25677846 — intervention group
Group type: EXPERIMENTAL
Intervention: best side improvement
Number of subjects: 28
Study 25677846 — intervention group
Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 28
Study 23782918 — intervention group
Group type: COMPARATOR
Intervention: Conventional Education (CE)
Number of subjects: 690
Study 23782918 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Education + Motivational Interviewing (CE+MI)
Number of subjects: 690
Study 23782918 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Education + Motivational Interviewing + Risk Assessment (CE+MI+RA)
Number of subjects: 690
Study 23782918 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CE, CE+MI, CE+MI+RA)
Number of subjects: 690
Study 20338067 — intervention group
Group type: EXPERIMENTAL
Intervention: Purell Instant Hand Sanitizer (1.6 g)
Number of subjects: 15
Study 20338067 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcare plus (1.6 g)
Number of subjects: 15
Study 20338067 — intervention group
Group type: COMPARATOR
Intervention: 2-propanol 60% (v/v) (control)
Number of subjects: 15
Study 20338067 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (1.6 g)
Number of subjects: 15
Study 18162061 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intracameral triamcinolone acetonide (TA)
Number of subjects: 60
Study 18162061 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% eyedrops (6 times per day for 7 days, then 4 times per day for 15 days)
Number of subjects: 60
Study 12736475 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic drug infusion for 10 min
Number of subjects: 27
Study 12736475 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous termination
Number of subjects: 27
Study 9583853 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for severe malnutrition
Number of subjects: 437
Study 8586153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg once daily
Number of subjects: 66
Study 8586153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 66
Study 2794184 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 25
Study 2794184 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 25
Study 2794184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2794184 — intervention group
Group type: COMPARATOR
Intervention: Comparison boys (without problems in attention and behavior)
Number of subjects: 25
Study 324389 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin (1.5 g/day)
Number of subjects: 25
Study 324389 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1.0 g/day)
Number of subjects: 25
Study 324389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31808984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone
Number of subjects: 0
Study 31808984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betamethasone
Number of subjects: 0
Study 31808984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 0
Study 31808984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 0
Study 31808984 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of betamethasone phosphate and betamethasone acetate
Number of subjects: 0
Study 30724740 — intervention group
Group type: EXPERIMENTAL
Intervention: ikherstel eHealth intervention
Number of subjects: 0
Study 28619307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 33
Study 28619307 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral intervention
Number of subjects: 33
Study 25992536 — intervention group
Group type: EXPERIMENTAL
Intervention: UPCR weighted by estimated daily urine creatinine excretion (eUCr)
Number of subjects: 120
Study 25992536 — intervention group
Group type: COMPARATOR
Intervention: Standard UPCR
Number of subjects: 120
Study 23937092 — intervention group
Group type: EXPERIMENTAL
Intervention: Blogging (writing about difficulties or free writing; either open or closed to responses)
Number of subjects: 156
Study 23937092 — intervention group
Group type: EXPERIMENTAL
Intervention: Blogging (writing about difficulties in blogs open to responses)
Number of subjects: 156
Study 23937092 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing a diary on personal computers
Number of subjects: 156
Study 23937092 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 156
Study 21342915 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 22
Study 21342915 — intervention group
Group type: COMPARATOR
Intervention: Placebo and 'tests alone' (non-ZA)
Number of subjects: 22
Study 19702681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surface implants (TiUnite, n = 45)
Number of subjects: 54
Study 19702681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid surface implants (Restore, n = 45)
Number of subjects: 54
Study 19702681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surface with microthreads implants (Hexplant, n = 45)
Number of subjects: 54
Study 17035507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering
Number of subjects: 0
Study 17035507 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15094401 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitopuncture stimuli on Dazhui (DU14) and Neiguan (PC6) points
Number of subjects: 40
Study 15094401 — intervention group
Group type: COMPARATOR
Intervention: Magnitopuncture applied to non-acupuncture points
Number of subjects: 40
Study 11509226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg, max 60 g males, 50 g females)
Number of subjects: 49
Study 11509226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 9624257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron + Dexamethasone
Number of subjects: 282
Study 9624257 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron alone
Number of subjects: 282
Study 7839102 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-positive patients
Number of subjects: 32
Study 7839102 — intervention group
Group type: COMPARATOR
Intervention: Patients with SS
Number of subjects: 32
Study 3351704 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially modified cow's milk formula
Number of subjects: 72
Study 3351704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free, casein-containing formula
Number of subjects: 72
Study 3351704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free, soy-protein-containing formula
Number of subjects: 72
Study 3351704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free, whey-hydrolysate-containing formula
Number of subjects: 72
Study 31818632 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic pain assessment
Number of subjects: 117
Study 31818632 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 117
Study 31402384 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV fusion (F) protein nanoparticle vaccine
Number of subjects: 50
Study 31402384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28663633 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine 0.2% (Group A)
Number of subjects: 96
Study 28663633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg with ropivacaine 0.2% (Group B)
Number of subjects: 96
Study 28663633 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine 0.2% with dexamethasone 8 mg (Group C)
Number of subjects: 96
Study 26491204 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid moisturizer applied from 2 weeks following whole-breast radiotherapy until 3 months after completion
Number of subjects: 62
Study 26491204 — intervention group
Group type: COMPARATOR
Intervention: No topical moisturizer during the study period
Number of subjects: 62
Study 23140912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 772
Study 23140912 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h glucose
Number of subjects: 772
Study 23140912 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG ≥126 mg/dl and HbA1c ≥6.5%
Number of subjects: 772
Study 21545942 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated percutaneous coronary intervention (fPCI)
Number of subjects: 1342
Study 21545942 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 1342
Study 19153828 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 285
Study 19153828 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus tamoxifen
Number of subjects: 285
Study 19153828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 285
Study 19153828 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment (Control)
Number of subjects: 285
Study 17258182 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment for one year
Number of subjects: 806
Study 17258182 — intervention group
Group type: COMPARATOR
Intervention: Control group (without simvastatin)
Number of subjects: 806
Study 15530262 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (100 mg/m(2))
Number of subjects: 119
Study 15530262 — intervention group
Group type: COMPARATOR
Intervention: Daily low-dose cisplatin (4 mg/m(2))
Number of subjects: 119
Study 11245768 — intervention group
Group type: EXPERIMENTAL
Intervention: GAITRite system
Number of subjects: 1
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker monotherapy
Number of subjects: 18790
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP target levels (DBP ≤ 90, DBP ≤ 85, DBP ≤ 80 mmHg)
Number of subjects: 18790
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (75 mg/day)
Number of subjects: 18790
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: Stricter blood pressure objective (DBP ≤ 80 mmHg)
Number of subjects: 18790
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: General treatment
Number of subjects: 18790
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight influence
Number of subjects: 18790
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 18790
Study 9749163 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP and SBP relationship
Number of subjects: 18790
Study 8168557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg daily
Number of subjects: 90
Study 8168557 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole regimen (10 mg twice daily) with Mycostatin (500,000 I.U. four times daily), Benadryl, and Cepacol mouthwash
Number of subjects: 90
Study 2894934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy (group 2)
Number of subjects: 258
Study 2894934 — intervention group
Group type: COMPARATOR
Intervention: Anal stretch (group 1)
Number of subjects: 258
Study 30410742 — intervention group
Group type: EXPERIMENTAL
Intervention: TrackCare GPS-based smartphone app for continuous location tracking
Number of subjects: 0
Study 30410742 — intervention group
Group type: COMPARATOR
Intervention: Mother's recall of care-seeking event
Number of subjects: 0
Study 28314838 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1,000 mg with prednisone 5 mg twice daily and BEZ235 200 mg twice daily
Number of subjects: 6
Study 25740751 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A and beta-carotene supplementation (placebo-controlled trial)
Number of subjects: 589
Study 25740751 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing IGF-1 levels
Number of subjects: 589
Study 24056209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushroom diet (n=36)
Number of subjects: 73
Study 22947814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS) condition
Number of subjects: 100
Study 22947814 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 100
Study 17636399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment for 2 years
Number of subjects: 564
Study 17636399 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 564
Study 17636399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 564
Study 16543298 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment team (127 participants)
Number of subjects: 251
Study 16543298 — intervention group
Group type: COMPARATOR
Intervention: Community mental health team (124 participants)
Number of subjects: 251
Study 12630606 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees Reverse Trendelenburg
Number of subjects: 26
Study 12630606 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine-Horizontal
Number of subjects: 26
Study 12630606 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees Back Up Fowler
Number of subjects: 26
Study 11186397 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation using 3 parallel cannulated screws
Number of subjects: 208
Study 11186397 — intervention group
Group type: COMPARATOR
Intervention: Uncemented Austin Moore hemiarthroplasty
Number of subjects: 208
Study 9122104 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration of the abscess
Number of subjects: 41
Study 9122104 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antibiotic treatment for suspected pyogenic abscess
Number of subjects: 41
Study 9122104 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cytological examination of aspirated abscess material
Number of subjects: 41
Study 1362746 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin‐clavulanic acid (2.2 g)
Number of subjects: 221
Study 1362746 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan (2 g)
Number of subjects: 221
Study 3873345 — intervention group
Group type: EXPERIMENTAL
Intervention: Murine antihuman T-cell monoclonal antibody (mcAb) therapy
Number of subjects: 25
Study 3873345 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antihuman thymocyte globulin (ATG)
Number of subjects: 25
Study 3873345 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent treatment with ATG after mcAb failure
Number of subjects: 25
Study 3873345 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity of mcAb therapy
Number of subjects: 25
Study 29083030 — intervention group
Group type: EXPERIMENTAL
Intervention: David's score
Number of subjects: 0
Study 29083030 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Elo-rating
Number of subjects: 0
Study 29083030 — intervention group
Group type: COMPARATOR
Intervention: Original Elo-rating
Number of subjects: 0
Study 29083030 — intervention group
Group type: COMPARATOR
Intervention: I&SI
Number of subjects: 0
Study 29083030 — intervention group
Group type: COMPARATOR
Intervention: ADAGIO
Number of subjects: 0
Study 29083030 — intervention group
Group type: EXPERIMENTAL
Intervention: Two simple methods for estimating uncertainty
Number of subjects: 0
Study 29083030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of observed interactions to individuals
Number of subjects: 0
Study 27180107 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NMR (faster nicotine metabolism) in White smokers
Number of subjects: 0
Study 27180107 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NMR (faster nicotine metabolism) in African American smokers
Number of subjects: 0
Study 27180107 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR groups and cotinine levels in African Americans
Number of subjects: 0
Study 27180107 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 enzyme activity in African Americans
Number of subjects: 0
Study 24595629 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive glycemia treatment
Number of subjects: 10251
Study 24595629 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive BP treatment
Number of subjects: 10251
Study 24595629 — intervention group
Group type: EXPERIMENTAL
Intervention: both intensive glycemia and BP treatment
Number of subjects: 10251
Study 24595629 — intervention group
Group type: COMPARATOR
Intervention: standard lipid/intensive glycemia
Number of subjects: 10251
Study 22734371 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-line puncture on the Governor Vessel and Bladder Meridian
Number of subjects: 60
Study 22734371 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (Yintang, Fengchi, Sishencong, Baihui, Shenting, Shangxing)
Number of subjects: 60
Study 20367677 — intervention group
Group type: EXPERIMENTAL
Intervention: Camouflage lessons
Number of subjects: 0
Study 20367677 — intervention group
Group type: COMPARATOR
Intervention: No camouflage (Control)
Number of subjects: 0
Study 19160946 — intervention group
Group type: EXPERIMENTAL
Intervention: Soldiers in close contact with the CPP
Number of subjects: 226
Study 19160946 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of male veteran soldiers with no CPP exposure
Number of subjects: 226
Study 16027568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based case management (CM) interventions
Number of subjects: 12